Another great psychedelics panel (I know what I like), chaired by @anadeutsch.bsky.social with presentations by her on data @hannamolla.bsky.social and I collected with Dr de Wit, Dr. Gibson Cook and Dr Helena Aicher #EBPS2025

What a perfect ending of #EBPS2025 super proud that I was the chair of this wonderful panel presenting their beautiful work on acute and chronic #cannabis effects. Excellent work @connorhaggarty.bsky.social @zivacooper.bsky.social Amir Englund & Lukas Eggeneberger 🤩

I had the pleasure of attending a psychedelics masterclass this afternoon chaired by Harriet de Wit with talks from Kathryn Cunningham, Chuck Nichols, @drfriid.bsky.social & @mayoonthebrain.bsky.social. From molecules to behaviour and practical steps in trial design #EBPS2025

Don't forget - poster abstract submissions for #ACNP2026 are due *this Thursday*, August 28th ⌛️

We still don’t know if microdosing psychedelics is effective or a placebo, but is it safe? Could microdosing activate cardiac 5HT2B receptors and cause valvulopathy? New work online at pubs.acs.org/doi/pdf/10.1... from @deffinger.bsky.social suggests that - at least in mice - the answer is no. 1/

📰 Another one! Le Point adds to the wide media coverage of our Psilocybin–Alcohol–Depression study. l.lepoint.fr/DYL France’s 1st psychedelic renaissance trial shows: ✨ society’s demand for new options as psychiatry & addiction care hit limits ✨ the need for rigorous science to test them.

Don't miss this 🆕 NPP Commentary on menstrual cycle and mental health in adolescents from @sibelnayman.bsky.social & Hannah Klusmann

Welcome to our newest @npp-journal.bsky.social Associate Editor, Dr. Kate Fitzgerald from @columbiapsych.bsky.social Be sure to check out our "Meet the Editor" episode with Dr. Fitzgerald below ⤵️

Want to be the next @npp-journal.bsky.social Editorial Intern? Or want to know more about what an Editorial Intern even does? Then check out the below thread and submit your application by July 30th! 👇

Another week is upon us, so it's time to check out what's new #ThisWeekInNPP We have an all dopamine lineup, see below for the latest in data-driven #dopamine insights ⤵️

The 2024 Impact Factors are out and we're happy to see NPP moving up to a 2024 Impact Factor of 7.1 🎉 We are grateful to the authors, reviewers, and editors who have contributed to so many stellar manuscripts this past year...and please, keep that 🔥 data coming!

We're back with another installment of #ThisWeekinNPP! ICYMI, every week we recap the latest articles from #NPP 🧐 #TWiNPP

New in @naturemedicine.bsky.social "An international Delphi consensus for reporting of setting in psychedelic clinical trials" by Chloé Pronovost-Morgan, Kyle Greenway, myself, and many ReSPCT Experts." nature.com/articles/s41...

Our latest "Meet the Author" interview with Dr. Francesco Bavato gives you the story behind how gamma-hydroxybutyrate (GHB) impacts sleep in MDD (interview by @brikchen.bsky.social & @drfriid.bsky.social ) Link to paper: www.nature.com/articles/s41... www.youtube.com/watch?v=SiKN...

We welcome you back from the long weekend (or - if outside the US - just a regular weekend) with what's new #ThisWeekInNPP See below for eCB-based interventions for PTSD, stress & sleep interactions, NMDA antagonists & working memory, plus info on a new cohort study⤵️

🔥New Paper🔥 Happy to share our latest research describing the oral bioavailability of #LSD for the first time and comparing different oral formulations #psychedelics doi.org/10.1002/cpt....

#ThisWeekInNPP New week – new science! 🧠 Explore the latest in neuropsychopharmacology research — from opioids to antipsychotics to recent findings on PTSD. 🧵👇

Congrats to @npp-journal.bsky.social whose podcasts were ranked #5 for Best Clinical Research Podcasts bit.ly/3RUupjJ and #10 for the Best Pharmacology Podcasts bit.ly/4k5Pcgb! All NPP podcast can be found at www.nature.com/npp/podcast

Symposium 2 explores the innovations and challenges in psychedelic research and how these advances are improving our understanding of behaviour and various mental health conditions chaired by Kathryn Cunningham #EBPS2025

Listen up 📢 it's time for another rundown of what's new #ThisWeekInNPP See below the latest science regarding nicotine smoking, cannabis use, ketamine, neuropathic pain, Parkinson's disease vulnerability, MDD & more (seriously - it's a 2-pager this week)⤵️

Hi everyone, if you are interested in #psychedelic-assisted therapy, we just published a new study: www.sciencedirect.com/science/arti.... Congratulations to Dr. Nathalie Rieser, who has done a terrific job spearheading this project.

Gather 'round - it's time for a 2-part edition of #ThisWeekInNPP See below for updates on ketamine, THC, stress-coping, mania, social threat and more 👇

📣📣📣 I am very happy to announce the first edition of the National Symposium of the #Psychedelic Medicine Section of the #AFPBN, taking place on Thursday, June 5th, 2025, at the Paris Brain Institute. www.afpbn.org/1st-national...

Check out the newest Brainpod Podcast on Endocannabinoid contributions to the perception of socially relevant, affective touch in humans a new study published in @npp-journal.bsky.social - bit.ly/Brainpod Full Study: go.nature.com/4hcjlbI @mayoonthebrain.bsky.social @connorhaggarty.bsky.social

It's time for another roundup of what's going on #ThisWeekInNPP See below for new articles on sleep in TRD 😴, alcohol & taste/smell 🧠 networks, neural mechanisms of behavioral flexibility in 🐀, novel ADHD treatments💊 & social stress in prairie vole relationships 💔

Check out what's new #ThisWeekInNPP - including novel insights into mechanisms underpinning clozapine's effects, interactions between methamphetamine and serotonin, & neural signatures of late-life depression ⤵️

It's time for another recap of what's new #ThisWeekInNPP See below for the newest @npp-journal.bsky.social papers on novel treatments for youth cannabis use disorder, interactions between opioid receptor availability and family environment, and factors contributing to postpartum depression ⤵️

In honor of Black History Month, we will share NPP resources for Black & URM trainees, re-visit evidence-based NPP articles showing the impacts of systemic racism & highlight Black NPP authors & @acnporg.bsky.social members who are improving our communities through research & advocacy 👇

Our latest research describes the treatment of a patient with neuropathic pain who was successfully treated with low-dose #MDMA #psychedelics www.frontiersin.org/journals/psy...

A new review of prep materials led by CPCR Faculty David Yaden (@existwell.bsky.social) shows psilocybin trial prep materials strongly emphasize safety yet can also shape participant expectations—highlighting a delicate balance between ensuring well-being and avoiding unintended bias.

It's a ✨new year✨ and we have some stellar new @npp-journal.bsky.social papers to share with you #ThisWeekInNPP 🥳 See below for new papers on designer drugs, psychedelics, TRD treatments, smoking & neuroinflammation, and cocaine craving ⤵️

Exiting new #DMT study investigating the dose-response relationship of 2h long DMT infusions and an exciting self-titration paradigm #psychedelics

So excited to welcome @drfriid.bsky.social to the NPP Special Projects team! 🥳

Join us in congratulating @npp-journal.bsky.social's new Editorial Intern, @drfriid.bsky.social 👏👏👏

Super excited to join the team!!🎉🔥

Guess who's joining the party over here?? 🎉🦋 @npp-journal.bsky.social @dpn-journal.bsky.social & @acnporg.bsky.social Be sure to follow☝️ahead of #ACNP2024

Hello psychedelic bsky! 1.) Phase 1 studies investigating the clinical pharmacology of psychedelics and phase 2 studies in mood disoders 2.) an fMRI analysis with data from an LSD-depression trial 3.) "The Crown" is the greatest soap of all time.

Our latest research dives into the potential mechanism of #MDMA induced hyponatremia and identifies #oxytocin as potential key factor. Good news: fluid restriction migitates the risk! ja.ma/3UURnsZ